Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study.

doi:10.1016/j.lungcan.2026.109560

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study.

Lung cancer (Amsterdam, Netherlands) - 1 Oct 2026

Masfarré Laura, Parreira Ana Sofia, Castro Natalia, Miquel Claudia, Navarro-Gorro Nil, Fabregat Raquel Marse, Bellvert Cristina Gomez, Fernandez Amaia Ariño, Serra Antonia Company, Aguillo Maite Martinez, Arasanz Hugo, Teijeira Lucia, Morilla Idoia, Rocha Pedro, Galindo Miguel, Clave Sergi, Taus Alvaro, Martinez Aitor Azkarate, Arriola Edurne

Abstract excerpt

BACKGROUND: KRAS is the most heterogeneous and frequent oncogenic driver in non-small cell lung cancer (NSCLC). KRAS alleles and co-mutations shape the tumour microenvironment, potentially influencing benefit from immune checkpoint inhibitors (ICI). The aim of our study was to evaluate the patterns of KRAS mutations, their correlation with clinical and pathological features and their association with ICI...

Read the complete abstract on PubMed

Topics

Humans
Lung Neoplasms
Female
Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Proto-Oncogene Proteins p21(ras)

Retrospective Studies

Mutation

Male

Immunotherapy

Aged

Middle Aged

Immune Checkpoint Inhibitors

Treatment Outcome

Aged, 80 and over

Prognosis

Adult

Source

Open in PubMed

Identifiers

PMID: 42607379
DOI: 10.1016/j.lungcan.2026.109560

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study.PMID 42607379Read ↗

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity Read ↗

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Clinicopathological Characteristics and Prognostic Impact of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.Semantic proximity Read ↗

[Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].Semantic proximity Read ↗

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read ↗

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 ImmunotherapySemantic proximity Read ↗

Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis.Semantic proximity Read ↗

Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.Semantic proximity Read ↗

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).Semantic proximity Read ↗

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.Semantic proximity Read ↗

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.